Roche opens major cardiovascular research centre in Boston

Up to 500 specialists will work at Roche’s new Boston research centre, giving the Basel based pharmaceutical group a larger platform in one of the world’s most concentrated life sciences markets.

Roche and its US subsidiary Genentech opened the Roche Genentech Innovation Centre at Harvard’s Enterprise Research Campus in Allston, a neighbourhood west of central Boston. The site will focus on cardiovascular, renal and metabolic diseases, areas that often overlap in patients and demand research across several medical disciplines.

The centre is designed to connect scientists working in basic research, clinical development, artificial intelligence and scientific data. Roche says the setup will allow projects to move from early discovery through advanced clinical development in one research environment.

The opening strengthens Roche’s American research presence as the company expands facilities and manufacturing capacity across the United States. It also gives the Swiss group direct access to Boston’s dense network of universities, hospitals, biotechnology companies and investors.

For Roche, the decision carries strategic weight. The company already employs around 25,000 people in the United States. Boston adds another major research address to a network that the group says includes 15 research and development centres and 13 manufacturing sites.

A 10-year lease covers 95,000 square metres, creating room for a large scientific operation rather than a small satellite office.

Roche says the Boston centre will combine laboratory science with clinical work and computational tools. That combination reflects the way drug development increasingly depends on large datasets, artificial intelligence and close links between laboratory findings and patient studies. The company has not disclosed a detailed staffing timetable or a financial breakdown for the Boston site.

Its disease focus is broad but connected. Cardiovascular, renal and metabolic conditions frequently appear together, and treatments in one area can affect outcomes in another. Bringing the relevant teams into a shared setting could support studies that examine these links from the earliest stages of research.

The facility sits within Harvard’s Enterprise Research Campus, placing Roche alongside an academic and commercial ecosystem that attracts scientists from around the world. The location also gives the company a base in Massachusetts, a state whose government has promoted its role as a global centre for biomedical discovery.

Roche chief executive Thomas Schinecker said the investment would expand the group’s US manufacturing and research footprint. He described scientific talent, capabilities and infrastructure as essential to developing future medicines.

Roche has tied the Boston project to a $50 billion commitment in the United States, covering manufacturing and research. The group says the programme builds on recent investments in Holly Springs, North Carolina, and Hillsboro, Oregon.

The expansion comes during a period of pressure on pharmaceutical supply chains. Possible US tariffs and incentives for domestic production have encouraged companies to examine where they conduct research, make medicines and build critical capacity. Swiss pharmaceutical groups have responded with investments across the United States, even as Switzerland remains a central base for corporate leadership, science and manufacturing.

Roche’s American footprint is already extensive. Its 15 research and development centres and 13 manufacturing sites support a workforce of around 25,000 employees across pharmaceuticals and diagnostics. The Boston centre adds specialist research capacity to that wider network.

The company’s approach also reflects the importance of proximity. Early scientific work, clinical development and manufacturing decisions increasingly need to be coordinated across borders and institutions. A major presence in Massachusetts can help Roche recruit researchers and maintain connections with hospitals, universities and emerging biotechnology firms.

The investment does not signal a withdrawal from Switzerland. Roche remains headquartered in Basel and continues to rely on Swiss expertise, infrastructure and regulation. It does show how the group is distributing growth across several innovation and production centres.